Literature DB >> 22569954

Evaluation of the supraaortic arteries using non-contrast-enhanced Velocity MR angiography "Inhance".

Nina Lummel1, Tobias Boeckh-Behrens, Juergen Lutz, Michael Burke, Jennifer Linn.   

Abstract

INTRODUCTION: The aim of this study was to compare the recently developed phase contrast-based Inhance 3D Velocity magnetic resonance angiography technique (Inhance) to the contrast-enhanced standard method (CE-MRA) in the evaluation of the supraaortic arteries.
METHODS: Inhance and CE-MRA were performed in ten consecutive patients with a suspected pathology of the supraaortic arteries on a 3-T MR scanner. Two neuroradiologists evaluated in consensus both sequences regarding the visualisation of the supraaortic arteries and their segments on a five-point score. Diagnostic certainty regarding the overall presence of a vascular pathology was rated on the same five-point score.
RESULTS: On CE-MRA as well as on Inhance, a vascular pathology of the supraaortic arteries was detected in seven patients. There was no statistically significant difference in the overall diagnostic certainty regarding the presence or absence of pathologic findings for CE-MRA compared to Inhance. Furthermore, no statistically significant difference was found with regard to visualisation of the distal cervical and intracranial arterial segments, while CE-MRA was superior to Inhance in the visualisation of the origins of the cervical vessels from the aortic arch.
CONCLUSION: Non-contrast Inhance proved useful in the evaluation of the supraaortic arteries with limited assessment of the proximal supraaortic branches. Hence, this technique features a valuable alternative to CE-MRA in the visualisation of the supraaortic arteries, particularly in patients with renal insufficiency.

Entities:  

Mesh:

Year:  2012        PMID: 22569954     DOI: 10.1007/s00234-012-1038-4

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  10 in total

1.  Contrast-enhanced 3D MR angiography of the carotid artery: comparison with conventional digital subtraction angiography.

Authors:  Luca Remonda; Pascal Senn; Alain Barth; Marcel Arnold; Karl-Olof Lövblad; Gerhard Schroth
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

2.  High-resolution, contrast-enhanced magnetic resonance angiography with elliptical centric k-space ordering of supra-aortic arteries compared with selective X-ray angiography.

Authors:  Ralf Wutke; Werner Lang; Claudia Fellner; Rolf Janka; Christan Denzel; Michael Lell; Werner Bautz; Franz A Fellner
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

3.  Supraaortic arteries: contrast-enhanced MR angiography at 3.0 T--highly accelerated parallel acquisition for improved spatial resolution over an extended field of view.

Authors:  Kambiz Nael; J Pablo Villablanca; Whitney B Pope; Thomas O McNamara; Gerhard Laub; J Paul Finn
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

4.  Contrast-enhanced MR angiography is not more accurate than unenhanced 2D time-of-flight MR angiography for determining > or = 70% internal carotid artery stenosis.

Authors:  L S Babiarz; J M Romero; E K Murphy; B Brobeck; P W Schaefer; R G González; M H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2009-01-22       Impact factor: 3.825

5.  3 T contrast-enhanced magnetic resonance angiography for evaluation of the intracranial arteries: comparison with time-of-flight magnetic resonance angiography and multislice computed tomography angiography.

Authors:  J Pablo Villablanca; Kambiz Nael; Reza Habibi; Ali Nael; Gerhard Laub; J Paul Finn
Journal:  Invest Radiol       Date:  2006-11       Impact factor: 6.016

6.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

7.  Contrast-free MRA at 3.0 T for the detection of intracranial aneurysms.

Authors:  M-H Li; Y-D Li; H-Q Tan; B-X Gu; Y-C Chen; W Wang; S-W Chen; D-J Hu
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

8.  Intracranial arteries: prospective blinded comparative study of MR angiography and DSA in 50 patients.

Authors:  K W Stock; E W Radue; A L Jacob; X S Bao; W Steinbrich
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

Review 9.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.

Authors:  Dale R Broome
Journal:  Eur J Radiol       Date:  2008-03-26       Impact factor: 3.528

Review 10.  Nephrogenic systemic fibrosis.

Authors:  Jeffrey C Weinreb; Phillip H Kuo
Journal:  Magn Reson Imaging Clin N Am       Date:  2009-02       Impact factor: 2.266

  10 in total
  4 in total

1.  Non-ECG-gated unenhanced MRA of the carotids: optimization and clinical feasibility.

Authors:  H Raoult; J Y Gauvrit; P Schmitt; V Le Couls; E Bannier
Journal:  Eur Radiol       Date:  2013-06-20       Impact factor: 5.315

2.  Diagnosis of Transverse Sinus Hypoplasia in Magnetic Resonance Venography: New Insights Based on Magnetic Resonance Imaging in Combined Dataset of Venous Outflow Impairment Case-Control Studies: Post Hoc Case-Control Study.

Authors:  Ke Han; A-Ching Chao; Feng-Chi Chang; Hung-Yi Hsu; Chih-Ping Chung; Wen-Yung Sheng; Lung Chan; Jiang Wu; Han-Hwa Hu
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

3.  Simultaneous Visualization of Vessels and Brain Tumor with Contrast-enhanced Three-dimensional Phase-contrast MR Imaging.

Authors:  Yutaka Shigenaga; Masato Sasaki; Takeshi Ishimoto; Keiko Ama
Journal:  Magn Reson Med Sci       Date:  2017-05-24       Impact factor: 2.471

4.  Non-contrast-enhanced magnetic resonance angiography of facial arteries for pre-operative evaluation of vascularized submental lymph node flaps.

Authors:  Ming-Chen Wu; Ming-Yi Hsu; Ren-Fu Shie; Ming-Huei Cheng; Fang-I Chu; Chien-Yuan Lin; Yui-Ping Fan; Sung-Yu Chu
Journal:  BMC Med Imaging       Date:  2019-08-16       Impact factor: 1.930

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.